Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer

Area of Science:

• Oncology
• Computational Biology
• Pharmacology

Background:

• Identifying synergistic chemotherapeutic drug combinations is a significant challenge in cancer treatment.
• Existing methods for predicting drug synergy are often limited in accuracy and scope.

Purpose of the Study:

• To introduce a novel computational approach, the Ranking-system of Anti-Cancer Synergy (RACS), for predicting synergistic drug combinations.
• To validate the efficacy of RACS across multiple cancer types and compare its performance against existing algorithms.

Main Methods:

• RACS integrates features from molecular targeting networks and cancer cell transcriptomic profiles.
• The system was validated using datasets from human B-cell lymphoma, breast cancer, and lung cancer (A549) cell lines.
• Experimental validation included in vitro confirmation and in vivo studies using a zebrafish xenograft model.

Main Results:

• RACS achieved a probability concordance of 0.78 for B-cell lymphoma, outperforming the previous best algorithm (0.61).
• Experimental validation confirmed 63.6% of breast cancer predictions, identifying four potent synergistic pairs.
• In vivo studies in a zebrafish model validated a synergistic drug combination with low toxicity.

Conclusions:

• The Ranking-system of Anti-Cancer Synergy (RACS) significantly enhances the prediction of drug synergy for cancer therapy.
• RACS offers a promising strategy to accelerate drug repurposing and reduce experimental prescreening for cancer treatments.
• Further research is needed to elucidate the underlying molecular mechanisms of identified synergistic drug interactions.